Biological research in the post-genomic era has become largely dependent on technologies allowing large-scale analysis of biological systems and processes. One of these approaches, Metabolomics, aims for a comprehensive and quantitative picture of small biomolecules such as sugars, lipids, and nucleic acids in biological samples, which can then be mapped on biochemical pathways.
We offer the analysis of user-defined compounds in extracts from biological samples by targeted liquid chromatography–tandem mass spectrometry (LC-MS/MS), including the respective methods development. In addition to relative quantification, the absolute quantification of metabolites is also offered (if the respective isotopically-labeled compounds are available). This approach can also be used to assess the quantitative changes in important biochemical pathways in biological samples by using panels of pre-defined analytes.
We also offer to develop tailor-made LC-MS/MS methods for all classes of metabolites.
The facility offers non-targeted metabolite profiling, employing high-resolution mass spectrometry. This technique aims for a hypothesis-free description of metabolic differences between samples caused by different genotypes or any perturbations of the system.
Using libraries containing tandem mass spectrometry data from known substances, a subset of these compounds can also be identified.
The TSQ Quantiva (Thermo Fisher Scientific) is a state-of-the-art triple quadrupole mass spectrometer, optimal for targeted analysis of small molecules. The mass spectrometer is on-line coupled to an Ultimate 3000 HPLC (Dionex; Thermo Fisher Scientific). This is a bio-inert HPLC, to be operated at micro-flow conditions. A metal-free flow path ensures low binding of biomolecules to surfaces, allowing the analysis of phosphorylated compounds.
If you want to start a new project, please contact Thomas Köcher to discuss your project and the analytical question. The unit offers both targeted and non-targeted analysis of metabolite-containing extracts and the respective methods development in a fee-for-service model. The facility does not accept radioactively-labeled samples. Deliverables are the relative (or absolute) quantities of the metabolites as defined by the user.
For more information, please see our usage policy.
The Metabolomics Core Facility offers access to its services to all users from both academia and companies on a “first come, first served"-basis, but prioritizes users from the participating institutes of the “shared research facility metabolomics”.
In addition, the VBCF General Cooperation Conditions apply.
For further questions, please contact Thomas Köcher.
We require acknowledgement of facility use in publications.
A simple statement is sufficient and can be placed in the Materials and Methods section or in the Acknowledgments section, depending on the journal format.
A simple statement in the acknowledgements is sufficient:
"The service xxxx was performed by the Metabolomics Facility at Vienna BioCenter Core Facilities (VBCF), member of the Vienna BioCenter (VBC), Austria and funded by the City of Vienna through the Vienna Business Agency".
Colaço HG, Barros A, Neves-Costa A, Seixas E, Pedroso D, Velho T, Willmann KL, Faisca P, Grabmann G, Yi HS, Shong M, Benes V, Weis S, Köcher T, Moita LF.  Immunity 53, 1-15.
Bonnay F, Veloso A, Steinmann V, Köcher T, Abdusselamoglu MD, Bajaj S, Rivelles E, Landskron L, Esterbauer H, Zinzen RP, Knoblich JA.  Cell 182 (6), 1490-1507
Rao S, Mondragón L, Pranjic B, Hanada T, Stoll G, Köcher T, Zhang P, Jais A, Lercher A, Bergthaler A, Schramek D, Haigh K, Sica V, Leduc M, Modjtahedi N, Pai TP, Onji M, Uribesalgo I, Hanada R, Kozieradzki I, Koglgruber R, Cronin SJ, She Z, Quehenberger F, Popper H, Kenner L, Haigh JJ, Kepp O, Rak M, Cai K, Kroemer G, Penninger JM.  Cell Research 29, 579–591
Muhar M, Ebert A, Neumann T, Umkehrer C, Jude J, Wieshofer C, Rescheneder P, Lipp JJ, Herzog VA, Reichholf B, Cisneros DA, Hoffmann T, Schlapansky MF, Bhat P, von Haeseler A, Köcher T, Obenauf AC, Popow J, Ameres SL, Zuber J.  Science 360, 800–805
Hörmann A, Hopfgartner B, Köcher T, Corcokovic M, Krammer T, Reiser C, Bader G, Shi J, Ehrenhöfer K, Wöhrle S, Schweifer N, Vakoc CR, Kraut N, Pearson M, Petronczki M, Neumüller RA.  Oncotarget. 9 (47), 28625-28637